Ayşe Durnalı

594 total citations
25 papers, 340 citations indexed

About

Ayşe Durnalı is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ayşe Durnalı has authored 25 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Ayşe Durnalı's work include Colorectal Cancer Treatments and Studies (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Sarcoma Diagnosis and Treatment (4 papers). Ayşe Durnalı is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Sarcoma Diagnosis and Treatment (4 papers). Ayşe Durnalı collaborates with scholars based in Türkiye, Kazakhstan and India. Ayşe Durnalı's co-authors include Berna Öksüzoğlu, Necati Alkış, Öznur Bal, Ülkü Yalçıntaş Arslan, Fatma Paksoy Türköz, Arife Ulaş, Osman Sönmez, Abdurrahman Işıkdoğan, Kamile Sılay and Ali̇ İnal and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Ayşe Durnalı

25 papers receiving 332 citations

Peers

Countries citing papers authored by Ayşe Durnalı

Since Specialization

Citations

This map shows the geographic impact of Ayşe Durnalı's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayşe Durnalı with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayşe Durnalı more than expected).

Fields of papers citing papers by Ayşe Durnalı

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayşe Durnalı. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayşe Durnalı. The network helps show where Ayşe Durnalı may publish in the future.

Co-authorship network of co-authors of Ayşe Durnalı

This figure shows the co-authorship network connecting the top 25 collaborators of Ayşe Durnalı. A scholar is included among the top collaborators of Ayşe Durnalı based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayşe Durnalı. Ayşe Durnalı is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study 2021 ·International Journal of Colorectal Disease ·(unknown), Kaplan Ma, Doğan Uncu, Mevlüde İnanç, Serap Kaya, Faysal Dane, Mehmet Küçüköner, (unknown), Mehmet Bilici, Ayşe Durnalı, (unknown), Mehmet Alı Nahıt Şendur, (unknown), (unknown), Ömer Fatih Ölmez, (unknown), Şahin Laçin, (unknown), Zuhat Urakçı, Abdurrahman Işıkdoğan	17
2	Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity? 2021 ·Expert Opinion on Drug Safety ·(unknown), Öznur Bal, Gökhan Uçar, Ayşe Durnalı, Yakup Ergün, (unknown), (unknown), Mutlu Doğan	1
3	Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit 2019 ·Irish Journal of Medical Science (1971 -) ·Öznur Bal, Berna Öksüzoğlu, Mutlu Doğan, Ayşe Durnalı, Ümmügül Üyetürk, (unknown), Ülkü Yalçıntaş Arslan, (unknown), Nuriye Yıldırım, Necati Alkış, Selim Kılıç	3
4	Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups 2016 ·PLoS ONE ·Ayşe Durnalı, Fatma Paksoy Türköz, (unknown), (unknown), (unknown), (unknown), Öznur Bal, (unknown), (unknown), Berna Öksüzoğlu, Necati Alkış	26
5	Risk Factors for Skeletal-Related Events in Patients with Non-Small Cell Lung Cancer Patients with Bone Metastases 2015 ·Annals of Oncology ·Arife Ulaş, Ahmet Bılıcı, (unknown), (unknown), Kamile Sılay, Fatma Paksoy Türköz, Ayşe Durnalı, (unknown), (unknown)	1
6	Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases 2015 ·Tumor Biology ·Arife Ulaş, Ahmet Bılıcı, Ayşe Durnalı, (unknown), (unknown), Kamile Sılay, Berna Öksüzoğlu, Necati Alkış	41
7	Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients. 2015 ·PubMed ·Öznur Bal, Ülkü Yalçıntaş Arslan, Ayşe Durnalı, (unknown), (unknown), Didem Taştekin, (unknown), (unknown), İbrahim Türker, Özlem Sönmez, Berna Öksüzoğlu	7
8	Recurrence Risk and Prognostic Parameters in Stage I Rectal Cancers 2014 ·Asian Pacific Journal of Cancer Prevention ·Şener Cihan, Mehmet Küçüköner, Nuriye Özdemir, Faysal Dane, Mehmet Alı Nahıt Şendur, (unknown), Zuhat Urakçı, Ayşe Durnalı, (unknown), Sercan Aksoy, (unknown), Mehmet Şeker, (unknown), Arzu Oğuz, Abdurrahman Işıkdoğan, Nurullah Zengin	2
9	Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience 2013 ·Oncology Letters ·Umut Kefeli, Mustafa Beneklı, Alper Sevinç, Ramazan Yıldız, Kaplan Ma, Aydın Çiltaş, (unknown), Abdurrahman Işıkdoğan, Uğur Çoşkun, Faysal Dane, Hakan Harputluoğlu, Halıt Karaca, (unknown), Ayşe Durnalı, Ali Kaya, Umut Demırcı, Mahmut Gümüş, Süleyman Buyukberber	9
10	Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients 2013 ·Medical Oncology ·Ayşe Durnalı, Necati Alkış, Şengül Cangür, (unknown), Ali̇ İnal, (unknown), Mehmet Şeker, Öznur Bal, (unknown), Mevlüde İnanç, Abdurrahman Işıkdoğan, (unknown), Kaan Helvacı, Berna Öksüzoğlu	64
11	Sunitinib-induced severe hypoglycemia in a diabetic patient 2013 ·Journal of Oncology Pharmacy Practice ·(unknown), Öznur Bal, Ayşe Durnalı, (unknown), (unknown), (unknown), Berna Öksüzoğlu	14
12	Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer 2012 ·Journal of Cancer Research and Clinical Oncology ·Ramazan Yıldız, Mustafa Beneklı, Metin Özkan, Necati Alkış, Velı Berk, Kaplan Ma, Aydın Çiltaş, Halıt Karaca, Ayşe Durnalı, Uğur Çoşkun, Mustafa Dikilitaş, Alper Sevinç, Faysal Dane, (unknown), (unknown), Süleyman Buyukberber	4
13	Metaplastic Breast Carcinoma: Case Series and Review of the Literature 2012 ·Asian Pacific Journal of Cancer Prevention ·(unknown), Fatma Paksoy Türköz, İbrahim Türker, Ayşe Durnalı, (unknown), Öznur Bal, Osman Sönmez, Burçin Budakoğlu, Ülkü Yalçıntaş Arslan, Berna Öksüzoğlu	50
14	XELOX versus FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer 2012 ·Hepatogastroenterology ·Velı Berk, Nuriye Özdemir, Metin Özkan, Sercan Aksoy, Nedim Turan, Ali̇ İnal, (unknown), Nurgül Yaşar, Olçun Ümit Ünal, Mustafa Beneklı, Ayşe Durnalı, (unknown), Özlem Sönmez	15
15	Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey 2012 ·Asian Pacific Journal of Cancer Prevention ·Ayşe Durnalı, (unknown), Nuriye Özdemir, Mevlüde İnanç, (unknown), Nurullah Zengin, Osman Sönmez, Mehmet Küçüköner	23
16	Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study. 2012 ·Journal of Clinical Oncology ·Kaplan Ma, Abdurrahman Işıkdoğan, Doğan Koca, Mehmet Küçüköner, Özge Gümüşay, Ramazan Yıldız, İlhan Öztop, Lütfiye Demir, Çağlayan Geredeli, Murat Koçer, Ülkü Yalçıntaş Arslan, Ali̇ İnal, Uğur Çoşkun, (unknown), Mevlüde İnanç, Emin Tamer Elkıran, Nuriye Özdemir, Ayşe Durnalı, Ali Süner, Süleyman Alıcı	1
17	Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study. 2012 ·PubMed ·Ali̇ İnal, (unknown), (unknown), Ramazan Yıldız, Velı Berk, (unknown), (unknown), (unknown), (unknown), Emin Tamer Elkıran, (unknown), Çağlayan Geredeli, (unknown), (unknown), Kaplan Ma, Ayşe Durnalı, (unknown), Gamze Göksel, Nuriye Özdemir, (unknown), (unknown), (unknown), Mustafa Beneklı, Abdurrahman Işıkdoğan	17
18	Primary adult soft tissue sarcomas: analysis of 294 patients 2010 ·Medical Oncology ·Necati Alkış, (unknown), Murat Koçer, Ülkü Yalçıntaş Arslan, Ayşe Durnalı, (unknown), (unknown), (unknown), Uğur Çoşkun	11
19	Primary gastric Hodgkin lymphoma and metachronous early gastric carcinoma: a case report 2010 ·Medical Oncology ·Ayşe Durnalı, (unknown), Necati Alkış, Arife Ulaş, Fatma Paksoy Türköz	4
20	Optimal timing of adjuvant treatment in patients with early breast cancer 2010 ·Medical Oncology ·Necati Alkış, Ayşe Durnalı, Ülkü Yalçıntaş Arslan, Murat Koçer, Fatih Oğuz Önder, (unknown), (unknown), (unknown), Güngör Utkan, Arife Ulaş, Kadri Altundağ	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact